COMMUNIQUÉS West-GlobeNewswire

Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
26/11/2025
Suite aux avis favorables rendus par le Comité des médicaments à usage humain (CMUH ) , la Commission européenne a accordé des autorisations de mise en marché visant les biosimilaires PONLIMSI et DEGEVMA de Teva, [...]
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
25/11/2025
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
25/11/2025
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
25/11/2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
25/11/2025
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patients IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG [...]
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
25/11/2025
HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
LENZ Therapeutics to Present at Upcoming Investor Conferences
25/11/2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1. [...]
Surrozen to Present at Upcoming Healthcare Investor Conferences
25/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
25/11/2025
Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and [...]
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
25/11/2025
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will [...]
Anaptys Announces Participation in December Investor Conferences
25/11/2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
25/11/2025
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
25/11/2025
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
25/11/2025
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b [...]
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
25/11/2025
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States SAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc [...]
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
26/11/2025
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 47 - 2025
25/11/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 17 Novembre au 21 Novembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 47 - 2025
25/11/2025
Aggregated presentation by day and by market Statement of transactions in own shares from November 17th to November 21st 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
UPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%
25/11/2025
Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market Important Disclaimer: This updated press release replaces and supersedes the version issued earlier this morning, which should be [...]

Pages